NASD · Healthcare · Biotechnology · USA
Dyne Therapeutics Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Dyne Therapeutics is a clinical-stage company developing therapeutics for genetically driven neuromuscular diseases using its proprietary FORCE platform. The platform delivers targeted payloads to muscle tissue and the central nervous system by leveraging transferrin receptor binding. The company is advancing product candidates for Duchenne muscular dystrophy, myotonic dystrophy, facioscapulohumeral dystrophy, and Pompe disease.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Dyne Therapeutics Inc stock.
Not valued: We cannot value this company yet.
17 more funds hold it; the full list is part of the paid plan.
129 more in this industry show a wider margin of safety.
We do not publish a verdict on DYN yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.
We do not publish one (as of the 2026-11-17 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.